Callan JMB Inc.

What they do

Callan JMB is a vertically integrated logistics and fulfillment company providing thermal management logistics solutions to the life sciences industry. It combines proprietary packaging, information technology including Sentry monitoring, and specialized cold chain know-how to ship frozen and cryogenic-temperature materials such as cell therapies, stem cells, vaccines, diagnostic materials, and bio-pharmaceuticals. The company positions its system as an alternative to dry ice and liquid nitrogen, offering shipment monitoring, recording, and archiving for scientific and regulatory purposes. It was originally formed as Coldchain Technology Services, LLC and reorganized as Callan JMB Inc. on January 24, 2024.

Revenue drivers

• Thermal management logistics services — Revenue comes from providing cold chain logistics and fulfillment for life sciences shipments, including monitoring, recording and archiving per-shipment data; this is the company's core and only described operating segment, generating $5.7M in 2025 revenue.
• Proprietary packaging and Sentry monitoring — The company sells proprietary packaging and Sentry monitoring as part of its cold chain system, which management says can address thermal management of temperature-sensitive packages and which it hopes to extend to GLP-1 transport, compounding pharmacies and high-end food packaging.
• Cross-selling across divisions — Management states its strategy includes identifying opportunities to cross-sell among and across its divisions, acting as a one-stop-shop provider and expanding services to existing customers; no separate division-level revenue figures are disclosed.

Recent performance

Revenue fell from $13.2M in 2023 to $6.6M in 2024 and $5.7M in 2025, while net income went from $2.2M positive in 2023 to a $2.3M loss in 2024 and an $8.0M loss in 2025. Operating cash flow dropped from $7.0M in 2023 to $540,353 in 2024 and negative $4.5M in 2025. For the six months ended June 30, 2026, revenue was $2,482,468 versus $3,115,687 a year earlier, with a net loss of $4,446,977 versus $2,641,986. Second-quarter 2026 revenue was $1,376,326 with a net loss of $1,231,923. At June 30, 2026, total assets were $4,451,058, total liabilities $3,769,195, stockholders' equity $681,863, and cash $860,273.

Strategy

Management's stated strategy is to leverage core competitive strengths, maintain relationships with a diversified customer group, and grow service lines. Principal elements include cross-selling solutions across divisions, expanding into additional markets such as pharmaceuticals, GLP-1 transport, compounding pharmacies and high-end food packaging, and executing cost, pricing and productivity initiatives through automation and process improvements. The company also flags expansion of its Sentry monitoring into new applications and describes a significant North American footprint for rapid response. No specific dollar amounts for planned investments are given in the excerpts.

Risks

• Delisting and listing-rule failures — The company disclosed delisting notices or listing-rule failures on 2026-04-10 and 2026-07-02, and the 10-K forward-looking statements reference an application for listing of its securities on Nasdaq.
• Recurring losses and cash burn — Net losses widened from $2.3M in 2024 to $8.0M in 2025, operating cash flow turned negative $4.5M in 2025, and cash fell to $860,273 at June 30, 2026 from $2,130,758 at December 31, 2025.
• Capital-intensive operations and financing needs — The 10-K risk factors state the business is capital intensive, requiring ongoing cash outlays that may strain available capital and force asset sales, debt, or equity issuance on unfavorable terms.
• Customer concentration and demand forecasting — Risk factors cite potential loss of or reduced purchasing by major customers and note that equipment and inventory purchasing decisions are based on demand forecasts that may prove inaccurate.

Outlook

The disclosed forward-looking items focus on the company's ability to achieve and maintain profitability, manage growth, access capital, and obtain approval for a Nasdaq listing. Management also expresses intent to expand its system into pharmaceuticals, GLP-1 transport, compounding pharmacies and high-end food packaging. The excerpts do not provide specific revenue, earnings, or cash flow guidance for future periods.